Acclaimed Pulitzer Prize-Winning Author, Oncologist and Cancer Researcher Siddhartha Mukherjee, MD Delivers Keynote Address
WASHINGTON, D.C. – Exploring the role of diagnostic innovation in the advancement of precision medicine and the federal policies impacting clinical laboratories was front and center today as congressional, administration, and industry leaders addressed meeting attendees at the American Clinical Laboratory Association’s (ACLA) 22nd annual conference in Washington, D.C.
“We are pleased to lead the public policy discussion today on diagnostic innovation and its impact on patient care,” said Julie Khani, president of the ACLA. “ACLA’s annual meeting brings together some of the most knowledgeable individuals in the industry and the broader stakeholder community to discuss the clinical laboratory community’s most pressing issues.”
Siddhartha Mukherjee, M.D., one of the foremost scientists leading revolutionary research on the complexities of cancer, gave the keynote address.
Other speakers included ACLA chairman Stephen H. Rusckowski, chairman, president and CEO of Quest Diagnostics Incorporated, as well as representatives from Hamilton Place Strategies, the Health and Human Services Office of the Inspector General, and the Centers for Medicare and Medicaid Services. Leaders from the diagnostic community, including Mayo Medical Laboratories, Hologic, Inc., Prognos, and Quest Diagnostics, joined a panel discussing how to elevate diagnostics and pathways to innovation. Representatives from the American Cancer Society Cancer Action Network, the National Health Council, March of Dimes, and Friends of Cancer Research, assembled on a second panel to offer their views on the role of laboratory diagnostics from the patient perspective.
To access the full agenda for ACLA’s annual conference at the Grand Hyatt Hotel, click here.
# # #
The ACLA is a not-for-profit association representing the nation’s leading national, regional and esoteric clinical laboratories on key issues of common concern, including federal and state government reimbursement and regulatory policies.